[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lipedema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lipedema":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,40,57,90,112,139,169,196,218,249,277,297,322,346,364,394,417,450,475,496,522,546],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100652795","the-relationship-between-lipedema-and-osteoporosis-100652795",false,"NCT07779603","The Relationship Between Lipedema and Osteoporosis","The Relationship Between Lipedema and Osteoporosis: A Cross-Sectional Observational Study","Inclusion Criteria:\n\n* being literate\n* voluntarily agreeing to participate in the study\n* being a postmenopausal woman\n* having a diagnosis of lipedema\n\nExclusion Criteria:\n\n* the presence of other types of edema in which a component other than lipedema predominates (e.g., lymphedema, venous edema, edema associated with heart or kidney failure, etc.)\n* chronic liver disease,\n* body mass index (BMI) of over 50.0 (this condition reflects severe obesity, which has a significant impact on health beyond lipedema alone)\n* the presence of rheumatological diseases that may lead to secondary osteoporosis\n* a history of cancer, endocrine disorders, neurological disorders, certain gastrointestinal disorders\n* use of medications related to osteoporosis\n* being under 18 years of age",true,"ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","1 Day","OBSERVATIONAL","The purpose of this study is to evaluate the relationship between lipedema and osteoporosis and to examine factors that may be associated with osteoporosis in individuals with lipedema.",[26,27],"Lipedema","Osteoporosis","NOT_YET_RECRUITING","2026-08-18",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":21},"2026-08-20",{"date":36,"type":21},"2026-09-16",{"name":38,"class":39},"Fatih Sultan Mehmet Training and Research Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":52,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":56,"locationsCount":4},"100652767","serum-magnesium-levels-in-patients-diagnosed-with-lipedema-100652767","NCT07779577","Serum Magnesium Levels in Patients Diagnosed With Lipedema","The Relationship Between Serum Magnesium Levels and Sleep Quality, Pain Levels, and Quality of Life in Patients Diagnosed With Lipedema: An Observational Cross-Sectional Study","Inclusion Criteria:\n\n* Serum magnesium levels must have been measured within the past 6 month\n* Be at least 18 years of age\n* Have a diagnosis of lipedema based on the Wold criteria\n* Have no cognitive or mental health issues\n* Agree to participate in the study\n\nExclusion Criteria:\n\n* No serum magnesium level measured within the past 6 months\n* Use of magnesium supplements for lipedema within the past 6 months, or the presence of any condition known to affect magnesium absorption or serum magnesium levels (e.g., use of a proton pump inhibitor \\[PPI\\] or diuretic)\n* The presence of other types of edema in which a component other than lipedema is predominant (e.g., lymphedema, venous edema, edema associated with heart or kidney failure, etc.)\n* A body mass index (BMI) of over 50.0 (this condition reflects severe obesity, which has a significant impact on health beyond lipedema alone)\n* Presence of a rheumatological disease, history of cancer, chronic liver disease, or endocrine disorder\n* Having been diagnosed with a psychiatric disorder, or use of psychiatric medications that may affect sleep\n* Being under 18 years of age",{"count":48,"type":21},128,"Female patients diagnosed with lipedema will be divided into two groups based on their Pittsburgh Sleep Quality Index (PSQI) scores: PSQI ≤ 5 and PSQI \\> 5. Age, body mass index (BMI), education level, menopausal status (reproductive period, perimenopausal period, postmenopausal period), number of births, duration of illness, occupation, marital status, disease stage, lipedema type, lower extremity functional scale, and the World Health Organization Quality of Life Scale - Short Form (Physical Health, Psychological Health, Social Relationships...)",[26,51],"Magnesium",{"date":31,"type":32},{"date":54,"type":21},"2026-08-16",{"date":36,"type":21},{"name":38,"class":39},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":74,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100650930","aquatic-versus-land-based-exercise-in-women-with-lipedema-100650930","NCT07756463","Aquatic Versus Land-Based Exercise in Women With Lipedema","Effects of Aquatic and Land-Based Exercise on Functional, Clinical, and Lymphatic Outcomes in Women With Lipedema: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women diagnosed with lipedema for at least five years\n* Had stage 2 or 3 and type 2 or 3 disease\n* Had a body mass index of ≥25 and \\\u003C40 kg\u002Fm²\n* Able to walk independently, with or without their usual assistive device\n* Had received medical clearance to participate in moderate-intensity aquatic and land-based exercise\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Had clinically significant lymphedema, uncontrolled chronic venous insufficiency, acute thrombosis, or another major cause of lower-limb edema\n* Had open wounds, active skin infection, fever, or another infectious condition incompatible with pool use\n* Had uncontrolled cardiovascular, metabolic, respiratory, or neurological disorder that could compromise exercise safety; a cardiac pacemaker or congestive heart failure; pregnancy; active cancer or ongoing chemotherapy, immunotherapy, or radiotherapy\n* Had history of bariatric surgery, recent major surgery, or liposuction; current use of weight-loss medication\n* Had current participation in structured aquatic or lower-limb exercise exceeding the protocol-defined threshold; or severe fear of water or inability to enter and exit the pool safely.","FEMALE","35 Years","45 Years",{"count":68,"type":21},60,"INTERVENTIONAL",[71],"NA","To evaluate optimal workout environments, a 12-week study assigned women with moderate-to-severe lipedema to three distinct protocols: supervised pool workouts, equivalent land-based training, or basic standard monitoring. Researchers tracked walking endurance alongside tissue composition, fluid levels, pain intensity, and general well-being. The trial posited that structured activity beats routine care alone, with water-based exercise potentially offering superior relief due to buoyancy and hydrostatic fluid compression.",[26],[75,76,77,78,79,80],"lipedema","hydrotherapy","therapeutic exercise","six-minute walk test","symptom burden","quality of life","2026-08-08",{"date":83,"type":32},"2026-08-11",{"date":85,"type":21},"2026-08-27",{"date":87,"type":21},"2027-10",{"name":89,"class":39},"Cairo University",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":97,"enrollmentInfo":98,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100650813","validity-and-reliability-of-the-2-minute-step-test-in-patients-with-lipedema-100650813","NCT07752017","Validity and Reliability of the 2-Minute Step Test in Patients With Lipedema","Construct Validity and Reliability of the 2-Minute Step Test in Patients With Lipedema: A Cross-Sectional Study","Inclusion Criteria:\n\n* Clinically diagnosed with lipedema according to the Wold and Halk-Damstra criteria, stage 2 and above\n* Aged 18-65 years, female\n* No walking-limiting pathology\n* Willing to participate\n\nExclusion Criteria:\n\n* Uncontrolled hypertension\n* Decompensated cardiac failure\n* Systemic, degenerative, neurological, rheumatological, or orthopedic disease affecting lower-extremity function\n* Lower-extremity surgery within the past 6 months\n* Peripheral artery disease causing vascular claudication\n* Severe psychiatric disorder (active psychosis, severe major depression) or cognitive impairment preventing compliance with test instructions\n* Neuromuscular disease\n* Pregnancy\n* Advanced-stage lipo-lymphedema severely restricting ambulation","65 Years",{"count":99,"type":21},55,"Lipedema is a chronic, progressive adipose tissue disorder that predominantly affects women and is characterized by symmetric, disproportionate subcutaneous fat accumulation in the lower extremities, pain, tenderness, and easy bruising. It is associated with reduced mobility and impaired functional capacity. Although the 2-Minute Step Test (2MST) is a practical, low-cost measure of functional capacity that requires no equipment or large space, its validity and reliability have not been investigated in patients with lipedema. The aim of this study is to evaluate the construct validity and test-retest reliability of the 2MST in women with lipedema.",[26],"2026-08-04",{"date":104,"type":32},"2026-08-07",{"date":106,"type":21},"2026-08-10",{"date":108,"type":21},"2027-04-10",{"name":110,"class":111},"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","OTHER_GOV",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":97,"enrollmentInfo":119,"targetDuration":4,"studyType":69,"phases":121,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100644028","efficacy-of-complex-decongestive-therapy-exercise-and-diet-in-women-with-lipedema-100644028","NCT07667270","Efficacy of Complex Decongestive Therapy, Exercise and Diet in Women With Lipedema","Efficacy of Complex Decongestive Therapy, Exercise, and Nutritional Interventions in Women Diagnosed With Lipedema: A Prospective, Single-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Female, aged 18 to 65 years.\n* Clinical and physical examination confirming Stage I, II, or III lipedema.\n* Body Mass Index (BMI) \\\u003C 45 kg\u002Fm\\^2.\n* Ability to walk without restriction.\n\nExclusion Criteria:\n\n* Presence of active malignancy.\n* Decompensated heart failure.\n* Significant lower extremity peripheral artery disease.\n* Acute deep vein thrombosis or active thromboembolism.\n* Pregnancy.\n* Significant sensory loss or severe neuropathy in the lower extremities.\n* History of lower extremity liposuction within the last 12 months.\n* Active severe infection (e.g., cellulitis).\n* Other severe systemic diseases deemed unsafe for the study by researchers.\n* Severe non-compliance with the study protocol (e.g., missing \\>30% of planned sessions) or participant requesting withdrawal.",{"count":120,"type":21},75,[71],"The purpose of this study is to compare the effectiveness of standard physical therapy methods (Complex Decongestive Therapy, Pneumatic Compression, and Exercise) combined with two different nutritional approaches (personalized anti-inflammatory diet vs. standard healthy nutrition education) in women diagnosed with lower extremity lipedema.",[26],[26,125,126,127,128],"diet","exercise","Complex Decongestive Therapy","Physical Therapy","2026-07-28",{"date":131,"type":32},"2026-07-29",{"date":133,"type":21},"2026-08-01",{"date":135,"type":21},"2027-12-15",{"name":137,"class":39},"Balikesir University",1,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":16,"sex":64,"minAge":18,"maxAge":97,"enrollmentInfo":146,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":138},"100648704","ultrasonographic-evaluation-and-pedobarographic-correlation-of-lower-extremity-muscles-in-lipedema-patients-100648704","NCT07724483","Ultrasonographic Evaluation and Pedobarographic Correlation of Lower Extremity Muscles in Lipedema Patients","PODUSG","Inclusion Criteria:\n\n* Female patients aged 18-65 years and diagnosed with lipedema by a clinician.\n* To agree to participate in the research.\n\nExclusion Criteria:\n\n* Positivity of Stemmer's sign (inability to compress the skin between the proximal phalanges of the 2nd and 3rd fingers)\n* Patients with Heart Failure\n* Patients with Chronic Kidney Disease\n* Motor neuron diseases or myositis\n* Diseases causing myositis\n* Patients diagnosed with polyneuropathy\n* Patients with motor-involved L3, L4, L5, or S1 radiculopathy\n* Those unable to ambulate independently\n* Those who cannot tolerate the assessments\n* Pregnant women\n* Congenital or traumatic lower extremity disorders (e.g., developmental hip dysplasia, previous lower extremity fractures with orthopaedic implants).",{"count":147,"type":21},90,"This study aims to investigate the relationship between lower extremity muscle\u002Ftendon characteristics and walking\u002Fbalance functions in women with lipedema. Lipedema is a condition characterized by abnormal fat accumulation that can lead to walking difficulties and joint problems. We will use ultrasonography to measure muscle thickness and tendon structures, and a pedobarography system to analyze foot pressure distribution during standing and walking. By comparing 45 patients with 45 healthy volunteers, we aim to identify the musculoskeletal causes of gait disorders in lipedema to help develop better prevention and treatment strategies",[26],[26,151,152,153,154,155,156,157,158],"Pedobarography","Musculoskeletal Ultrasound","Rectus Femoris","Gastrocnemius","Posterior Tibialis","Gluteus Medius","Achilles","STAR","RECRUITING","2026-07-21",{"date":162,"type":32},"2026-07-24",{"date":164,"type":32},"2026-07-15",{"date":166,"type":21},"2026-09-15",{"name":168,"class":39},"Marmara University",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100648635","turkish-validation-of-the-rapprich-lipedema-symptomatic-assessment-questionnaire-100648635","NCT07725146","Turkish Validation of the Rapprich Lipedema Symptomatic Assessment Questionnaire","Turkish Validity and Reliability of the Rapprich Lipedema Symptomatic Assessment Questionnaire","RapprichTR","Inclusion Criteria:\n\n* Female patients aged 18-75.\n* Diagnosed with lipedema by a clinician.\n* Willingness to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Positive Stemmer sign or presence of advanced-stage lymphedema.\n* Diagnosis of Heart Failure.\n* Chronic Kidney Disease.\n* Pregnancy.\n* BMI \\> 50 kg\u002Fm².","75 Years",{"count":179,"type":21},180,"Lipedema is a chronic disease characterized by abnormal fat accumulation, primarily in the lower extremities, affecting women. This study aims to evaluate the validity and reliability of the Turkish version of the Rapprich Lipedema Symptomatic Assessment Questionnaire, which was originally developed by Rapprich et al. in 2010. Since a validated Turkish version is currently unavailable, this research will provide a standardized tool for clinicians to assess symptomatic severity in Turkish-speaking lipedema patients.",[26],[26,183,184,185,186,187,188],"Rapprich Questionnaire","Symptom Assessment","Turkish","Cultural Adaptation","Adipose Tissue Diseases","Quality of Life",{"date":162,"type":32},{"date":191,"type":32},"2026-07-17",{"date":193,"type":21},"2027-03-15",{"name":168,"class":39},2,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":97,"enrollmentInfo":203,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":138},"100640028","assessment-of-venous-insufficiency-and-clinical-features-in-lipedema-100640028","NCT07603076","Assessment of Venous Insufficiency and Clinical Features in Lipedema","Evaluation of Venous Insufficiency and Its Association With Clinical Features in Patients With Lipedema: A Cross-Sectional Study","Inclusion Criteria:\n\n* Female participants aged 18 years or older\n* Clinically diagnosed lipedema according to established diagnostic criteria\n* Ability to provide written informed consent\n* Ability to complete clinical assessments and questionnaires\n\nExclusion Criteria:\n\n* History of lower extremity venous surgery or sclerotherapy\n* Known peripheral arterial disease\n* Secondary lymphedema or other causes of lower extremity edema\n* Active infection, cellulitis, or inflammatory disease affecting the lower extremities\n* Pregnancy or postpartum period\n* Neurological, rheumatological, or musculoskeletal disorders significantly affecting lower extremity function\n* Malignancy or severe systemic disease\n* Inability to undergo venous Doppler ultrasonography\n* Inability to understand or complete study assessments and questionnaires",{"count":204,"type":21},82,"Lipedema is a chronic adipose tissue disorder characterized by disproportionate fat accumulation, pain, tenderness, edema, and functional impairment. Venous symptoms such as heaviness, swelling, and discomfort are frequently reported in individuals with lipedema; however, the relationship between venous Doppler ultrasonography findings and lipedema-related clinical manifestations remains insufficiently investigated. This cross-sectional controlled study aims to evaluate venous insufficiency parameters in patients with lipedema using Doppler ultrasonography and to examine their associations with pain severity, lower extremity function, disease severity, and quality of life.",[26,207,208,209],"Venous Insufficiency","Venous Disease","Disability Physical","2026-07-13",{"date":212,"type":32},"2026-07-14",{"date":214,"type":32},"2026-06-20",{"date":133,"type":21},{"name":217,"class":39},"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":64,"minAge":225,"maxAge":97,"enrollmentInfo":226,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":228,"conditions":229,"keywords":237,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":247,"locationsCount":195},"100639251","the-effect-of-lipedema-on-knee-osteoarthritis-100639251","NCT07575555","The Effect of Lipedema on Knee Osteoarthritis","The Effect of Lipedema on Knee Osteoarthritis: A Cross-Sectional Analysis of Clinical Symptoms and Ultrasonographic Findings","Inclusion Criteria:\n\nAll participants (Group 1 + Group 2)\n\n* Women aged 30-65\n* With a clinical and radiological diagnosis of knee osteoarthritis\n* Who agreed to participate in the study\n\nGroup 1 (knee osteoarthritis with lipedema):\n\n* Patients who meet the Wold criteria for a clinical diagnosis of lipedema\n* An increase in subcutaneous fat thickness confirmed by ultrasound\n\nGroup 2 (knee osteoarthritis without lipedema):\n\n* No diagnosis of lipedema\n* Exclusion of lymphedema and venous diseases\n\nExclusion Criteria:\n\n* Inflammatory arthritis\n* History of knee surgery\n* Intra-articular injection within the past 6 months\n* Acute trauma\n* Systemic connective tissue disease\n* Severe venous insufficiency or lymphedema\n* History of malignancy\n* Use of gabapentinoids\u002FSNRIs\u002FSSRIs due to fibromyalgia or psychiatric illness\n* Severe cognitive impairment or communication problems that would prevent participation in the study\n* Pregnancy\n* Participants who were informed about the study and refused to participate","30 Years",{"count":227,"type":21},76,"This study will be one of the few to examine the effect of lipedema on knee osteoarthritis in a comparative manner with a control group within the same osteoarthritis context. Although the relationship between obesity and osteoarthritis has been extensively studied in the literature, the effect of specific adipose tissue pathologies, such as lipedema, on osteoarthritis has not been sufficiently investigated. This study aims to demonstrate the independent effect of lipedema on osteoarthritis, evaluate clinical and ultrasonographic parameters together, and contribute to early diagnosis and targeted rehabilitation strategies.",[26,230,231,232,233,234,235,236],"Knee Osteoarthritis","Knee Acute and Chronic Pain","Knee","Knee Arthritis Osteoarthritis","Knee Arthropathy","Knee Cartilage Defects","Knee Cartilage Lesions",[75,238,239,240],"knee osteoarthritis","knee joint","knee","2026-07-07",{"date":243,"type":32},"2026-07-09",{"date":241,"type":32},{"date":246,"type":21},"2027-08-15",{"name":248,"class":39},"Izmir Democracy University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":177,"enrollmentInfo":257,"targetDuration":4,"studyType":69,"phases":259,"briefSummary":260,"conditions":261,"keywords":262,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":273,"leadSponsor":275,"locationsCount":138},"100647054","extracorporeal-shock-wave-therapy-in-patients-with-lipedema-100647054","NCT07683559","Extracorporeal Shock Wave Therapy in Patients With Lipedema","Evaluation of the Effects of Extracorporeal Shock Wave Therapy on Pain, Quality of Life, and Ultrasonographic Findings in Patients With Lipedema","LIPO-ESWT","Inclusion Criteria:\n\n* Male or female participants aged 18 to 75 years\n* Clinical diagnosis of lipedema\n* Willingness to participate and provide written informed consent\n* Ability to comply with study procedures and follow-up assessments\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Active infection in the treatment area\n* Malignancy\n* Severe cardiovascular disease\n* Coagulation disorders or current anticoagulant therapy\n* Previous ESWT treatment within the last 6 months\n* Severe psychiatric or cognitive disorders interfering with study participation\n* Any condition deemed by the investigator to make participation unsafe",{"count":258,"type":21},40,[71],"Lipedema is a chronic adipose tissue disorder characterized by pain, tenderness, disproportionate fat accumulation, and impaired quality of life. Extracorporeal shock wave therapy (ESWT) has been proposed as a non-invasive treatment option that may improve pain and tissue characteristics in patients with lipedema.\n\nThe aim of this prospective interventional study is to evaluate the effects of ESWT on pain intensity, quality of life, functional outcomes, and ultrasonographic findings in patients diagnosed with lipedema. Participants will receive a standardized ESWT protocol consisting of six treatment sessions over a two-week period. Clinical assessments and ultrasonographic examinations will be performed before and after treatment.",[26],[263,264,26,265,266,188,267,268],"Extracorporeal Shock Wave Therapy","ESWT","Pain","Ultrasonography","PROMIS","Patient-Reported Outcomes","2026-07-01",{"date":271,"type":32},"2026-07-06",{"date":269,"type":21},{"date":274,"type":21},"2027-01-01",{"name":276,"class":39},"Atlas University",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":16,"sex":64,"minAge":18,"maxAge":97,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":293,"leadSponsor":295,"locationsCount":4},"100641696","serum-maresin-1-levels-in-patients-with-lipedema-a-cross-sectional-study-100641696","NCT07651813","Serum Maresin-1 Levels in Patients With Lipedema: A Cross-Sectional Study","Evaluation of the Relationship Between Serum Maresin-1 Levels and Clinical and Inflammatory Parameters in Patients With Lipedema","LIP-MARES","Inclusion Criteria:\n\n* Female participants aged 18 to 65 years. Women with a clinical diagnosis of lipedema for the lipedema group. Women with obesity (body mass index ≥30 kg\u002Fm²) and without a diagnosis of lipedema for the obesity group.\n\nHealthy female volunteers without chronic or inflammatory diseases for the healthy control group.\n\nNo acute infection within the previous 3 months. Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Active infection at the time of enrollment. History of autoimmune or chronic inflammatory disease. History of malignancy. Pregnancy or breastfeeding. Current use of corticosteroids or immunosuppressive medications. Regular use of anti-inflammatory medications that may affect inflammatory biomarkers.\n\nAcute infection within the previous 3 months. Inability to comply with study procedures or complete study assessments. Refusal or inability to provide written informed consent.",{"count":286,"type":21},84,"Lipedema is a chronic and progressive adipose tissue disorder characterized by symmetrical fat accumulation, pain, tenderness, and easy bruising, predominantly affecting women. Increasing evidence suggests that chronic low-grade inflammation and impaired resolution of inflammation may contribute to its pathophysiology. Maresin-1 is a specialized pro-resolving lipid mediator with potent anti-inflammatory and tissue-protective properties; however, its role in lipedema remains largely unknown. This cross-sectional observational study aims to evaluate serum Maresin-1 levels in women with lipedema and to investigate their associations with pain severity, inflammatory markers, central sensitization, and quality of life. Serum Maresin-1 levels and clinical characteristics will be compared among women with lipedema, obese women without lipedema, and healthy controls to explore the potential value of Maresin-1 as a biomarker in lipedema.",[26],"2026-06-11",{"date":291,"type":32},"2026-06-16",{"date":214,"type":21},{"date":294,"type":21},"2026-09-01",{"name":296,"class":39},"Kanuni Sultan Suleyman Training and Research Hospital",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":16,"sex":64,"minAge":18,"maxAge":177,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":319,"leadSponsor":320,"locationsCount":138},"100630559","multimodal-ultrasound-for-differentiating-lymphedema-and-lipedema-100630559","NCT07489248","Multimodal Ultrasound for Differentiating Lymphedema and Lipedema","ULTRASONOGRAPHIC EVALUATION OF LOWER EXTREMITY SKIN AND SUBCUTANEOUS TISSUE WITH QUANTITATIVE ECHOGENICITY AND ELASTOGRAPHY IN LYMPHEDEMA, LIPEDEMA, AND HEALTHY CONTROL GROUPS: A CONTROLLED CLINICAL STUDY","Inclusion Criteria:\n\nIndividuals aged 18 to 75 years.\n\nClinical diagnosis of lower extremity lymphedema (for the lymphedema group).\n\nClinical diagnosis of lower extremity lipedema (for the lipedema group).\n\nHealthy individuals with no history or clinical signs of chronic lower extremity edema (for the control group).\n\nExclusion Criteria:\n\nPresence of active local infections, such as cellulitis or erysipelas, in the lower extremities.\n\nHistory of deep vein thrombosis (DVT) or severe chronic venous insufficiency.\n\nSystemic conditions that can cause secondary edema, including congestive heart failure, chronic kidney disease, or severe hepatic impairment.\n\nPrevious surgical interventions on the affected lower extremities, including liposuction, lymphatic reconstructive surgery, or major orthopedic surgeries.\n\nActive malignancy or currently undergoing radiotherapy\u002Fchemotherapy.\n\nPregnancy or lactation.",{"count":120,"type":21},"The aim of this observational study is to evaluate the diagnostic value of multimodal ultrasonography in differentiating between lymphedema and lipedema. Differentiating these two chronic conditions based solely on clinical examination can be challenging due to overlapping symptoms. This study will utilize various non-invasive ultrasound techniques-including B-mode ultrasound, strain elastography, power Doppler, and quantitative ImageJ analysis-to compare tissue characteristics among patients with lymphedema, patients with lipedema, and healthy controls. The goal is to identify reliable, non-invasive imaging biomarkers that can facilitate early and accurate diagnosis, thereby optimizing patient management.",[307,26],"Lymphedema",[309,310,311,312,313,314],"Multimodal Ultrasonography","Strain Elastography","Differential Diagnosis","Power Doppler","ImageJ Analysis","Subcutaneous Tissue","2026-03-19",{"date":317,"type":32},"2026-03-24",{"date":315,"type":32},{"date":166,"type":21},{"name":321,"class":111},"Kayseri City Hospital",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":331,"conditions":332,"keywords":335,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":343,"leadSponsor":345,"locationsCount":138},"100628934","the-impact-of-metabolic-status-on-pain-and-central-sensitization-in-women-with-lipedema-a-cross-sectional-observational-study-100628934","NCT07468097","The Impact of Metabolic Status on Pain and Central Sensitization in Women With Lipedema: A Cross-Sectional Observational Study","THE IMPACT OF METABOLIC STATUS ON PAIN AND CENTRAL SENSITIZATION IN WOMEN WITH LIPEDEMA: A CROSS-SECTIONAL OBSERVATIONAL STUDY","Inclusion Criteria:\n\n* Being female and aged 18 years or older\n* Having chronic pain persisting for at least 3 months\n* Having sufficient cognitive ability to understand and respond to the assessment scales used in the study\n* Voluntarily agreeing to participate in the study and providing written informed consent\n\nExclusion Criteria:\n\n* Presence of a history of malignancy, active infection, inflammatory rheumatic disease, or severe systemic disease\n* History of known neurological disorders (e.g., stroke, multiple sclerosis, epilepsy)\n* Diagnosis of severe psychiatric disorders (e.g., psychotic disorders, bipolar disorder)\n* Pregnancy or breastfeeding\n* Presence of cognitive impairment or communication difficulties that could affect the study results\n* Diagnosed diabetes mellitus\n* Active thyroid disease (uncontrolled hypothyroidism or hyperthyroidism)\n* Cushing's syndrome or other significant endocrine disorders\n* Use of antidiabetic medications\n* Use of lipid-lowering therapy (e.g., statins, fibrates)\n* Systemic glucocorticoid use within the past 3 months\n* Use of medications that may significantly affect central pain mechanisms (e.g., high-dose opioids, antipsychotic drugs)\n* History of major surgery or invasive treatment for pain within the past 3 months",{"count":330,"type":21},59,"The aim of this study is to evaluate the effect of metabolic markers (HOMA-IR, triglyceride\u002FHDL ratio, HbA1c, waist and hip circumference measurements, BMI, etc.) on pain and central sensitization in patients diagnosed with lipedema. The primary objective is to investigate the association between metabolic markers and central sensitization. The secondary objective is to assess the relationship between metabolic markers and pain intensity, pain phenotype, and functional status.",[333,26,265,334],"Central Sensitization","HOMA-IR",[336,334,265,337,338,26],"Triglyceride","Fasting Blood Glucose","Fasting Insulin","2026-03-09",{"date":341,"type":32},"2026-03-12",{"date":339,"type":32},{"date":344,"type":21},"2027-03-01",{"name":168,"class":39},{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":64,"minAge":225,"maxAge":66,"enrollmentInfo":4,"targetDuration":4,"studyType":353,"phases":4,"briefSummary":354,"conditions":355,"keywords":356,"overallStatus":359,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":363,"locationsCount":138},"100624009","effect-of-ultrasound-cavitation-versus-pneumatic-compression-on-adipose-tissue-thickness-on-lipedema-patients-100624009","NCT07404059","Effect of Ultrasound Cavitation Versus Pneumatic Compression on Adipose Tissue Thickness on Lipedema Patients","The Effect of Fat Cavitation Versus Pneumatic Compression on Adipose Tissue Thickness in Patients With Lipedema","Inclusion Criteria:\n\n1. Ninety females patients their age from 30 to 45 years\n2. Diagnosed with mild to moderate lipedema\n3. Mentally stable functionally and physically stable.\n\nExclusion Criteria:\n\n1. Patents with severe lipedema\n2. Patients with type 4 lipedema\n3. Clinically unstable patients\n4. Patients with chronic diseases\n5. Patients with endocrine diseases\n6. Patienst with similar conditions like lymphedema, dercum's diseases or overall obesity\n7. Patients with lower limbs fractures","EXPANDED_ACCESS","PURPOSE:\n\nThis study will be conducted to investigate any significant effect of ultrasound fat cavitation or pneumatic compression on adipose tissue thickness in patients with lipedema.\n\nBACKGROUND:\n\nLipedema is a connective tissue disorder that cause physical discomfort and psychological stress.\n\nA literature review published in 2020 estimated that 10-11% of women or approximately 400 million women across the globe have lipedema.\n\nLipedema fat is dangerous when it progress onto abdomen and trunk resulting in a risk of developing high blood pressure, high cholesterol and diabetes.\n\nUltrasound cavitation is a safe cosmetic procedure has almost no adverse reactions used to break down fat cells under the skin which improves the body shape and reduce circumference which make it a promising non invasive tool alternative to surgical liposuction.\n\nPneumatic compression is bl=elieved to reduce the limb circumference and volume which make it a good treatment option for lipedema.\n\nHYPOTHESES:\n\nNull Hypothesis:there will be no significant effect of fat cavitation or pneumatic compression on the adipose tissue thickness in patients with lipedema.\n\nRESEARCH QUESTION:Will be any significant effect of fat cavitation or pneumatic compression on the adipose tissue thickness in patients with lipedema",[26],[357,358,75],"pneumatic compression","fat cavitation","AVAILABLE","2026-02-04",{"date":362,"type":32},"2026-02-11",{"name":89,"class":39},{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":16,"sex":64,"minAge":18,"maxAge":97,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":373,"conditions":374,"keywords":378,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":138},"100615546","investigation-of-medial-longitudinal-arch-and-foot-function-in-patients-with-lipedema-100615546","NCT07294014","Investigation of Medial Longitudinal Arch and Foot Function in Patients With Lipedema","Investigation of Medial Longitudinal Arch and Foot Function in Patients With Lipedema: A Cross-Sectional Study","General Inclusion Criteria (Apply to All Participants)\n\n* Female participants\n* Age 18 years or older\n* Able to read and write (literacy requirement)\n* Availability of bilateral lateral foot radiographs obtained within the past 1 year in the hospital PACS system\n* Willing and able to provide written and verbal informed consent\n\nAdditional eligibility criteria for Lipedema Group\n\n\\- Clinical diagnosis of lipedema according to Halk and Damstra criteria.\n\nAdditional eligibility criteria for Control group:\n\n* Female patients presenting with nonspecific foot pain\n* Similar age and BMI range as the lipedema group\n* No clinical diagnosis or suspicion of lipedema\n\nExclusion Criteria (Apply to all participants)\n\n* Pregnancy\n* Illiteracy\n* Inability or unwillingness to provide written and verbal informed consent\n* History of lower extremity fracture, trauma, or orthopedic surgery\n* Diagnosis of diabetes mellitus\n* Known rheumatologic disease\n* Known polyneuropathy or peripheral nerve injury affecting the lower extremities",{"count":372,"type":21},32,"Lipedema is a chronic adipose tissue disorder that commonly leads to joint laxity, hypermobility, and functional limitations, yet its impact on foot morphology has not been systematically examined. This case-control study aims to investigate whether patients with lipedema exhibit a higher prevalence of generalized joint hypermobility and foot structural abnormalities-specifically pes planus-compared with age- and BMI-matched controls. Using radiographic measurements (Meary angle and calcaneal inclination angle), clinical hypermobility assessment, and validated functional scales, the study seeks to determine the relationship between lipedema, hypermobility, and foot function.",[26,375,376,377],"Hypermobility Syndrome (Disorder)","Pes Planus","Joint Hypermobility",[75,379,380,381,382,383,384,385],"mypermobility","foot function","pes planus","joint hyper mobility","foot morphology","Meary angle","calcaneal inclination angle","2025-12-31",{"date":388,"type":32},"2026-01-02",{"date":390,"type":21},"2026-01-01",{"date":392,"type":21},"2026-04-01",{"name":168,"class":39},{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":97,"enrollmentInfo":400,"targetDuration":4,"studyType":69,"phases":402,"briefSummary":403,"conditions":404,"keywords":407,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":416,"locationsCount":138},"100617514","investigation-of-the-effects-of-high-intensity-interval-exercise-and-moderate-intensity-continuous-exercise-on-limb-volume-functional-capacity-and-quality-of-life-in-patients-with-lipedema-100617514","NCT07319611","Investigation of the Effects of High-Intensity Interval Exercise and Moderate-Intensity Continuous Exercise on Limb Volume, Functional Capacity, and Quality of Life in Patients With Lipedema","Inclusion Criteria:\n\n* Female participants aged 18-65 years\n* Able to read and write (literate)\n* Clinically diagnosed with lipedema according to Halk and Damstra criteria\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Illiteracy\n* Refusal or inability to provide written\u002Fsigned consent\n* Lower extremity fracture, trauma, or surgery within the past 12 months\n* Cardiopulmonary diseases that contraindicate exercise participation\n* Development of intolerance exercise sessions",{"count":401,"type":21},69,[71],"This randomized controlled clinical study aims to investigate and compare the effects of high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT), when combined with intermittent pneumatic compression (IPC) therapy, on limb volume, functional capacity, pain, fatigue, anxiety, depression, sleep quality, and quality of life in women with lipedema.\n\nLipedema is a chronic, progressive adipose tissue disorder primarily affecting women, characterized by abnormal and symmetrical fat accumulation in the lower extremities that does not improve with weight loss or limb elevation. It is often misdiagnosed as obesity or lymphedema, leading to delayed treatment. Lipedema causes pain, swelling, bruising, mobility limitation, and reduced quality of life.\n\nConservative treatment options include compression therapy, manual lymphatic drainage, and exercise. IPC is a non-invasive treatment used to reduce limb volume and pain while improving function and quality of life. Exercise is also a cornerstone of conservative management, but the optimal exercise intensity for lipedema remains unclear.\n\nIn this study, 69 female patients aged 18-65 years diagnosed with lipedema according to Halk and Damstra criteria will be randomly assigned into three groups:\n\nIPC + Home-based walking program\n\nIPC + High-Intensity Interval Training (HIIT)\n\nIPC + Moderate-Intensity Continuous Training (MICT)\n\nAll participants will receive 15 IPC sessions (3 times per week for 5 weeks). The exercise programs (HIIT or MICT) will continue for 10 weeks, supervised by a physiotherapist. The home-based group will be encouraged to walk ≥10,000 steps daily using a pedometer application.\n\nPrimary outcome: Change in limb volume measured by circumferential measurements and the truncated cone formula.\n\nSecondary outcomes: Pain (VAS), functional capacity (6-Minute Walk Test), muscle strength (dynamometry), pressure pain threshold (algometry), physical activity (IPAQ-SF), lower extremity function (LEFS), quality of life (SF-12), sleep quality (PSQI), fatigue (FSS), and anxiety\u002Fdepression (HADS).\n\nMeasurements will be taken at baseline (T0), after 15 IPC sessions (T1), and after 30 total sessions or 10 weeks (T2).\n\nThe investigators hypothesize that both HIIT and MICT combined with IPC will provide superior improvements in physical and psychological outcomes compared to IPC with a home-based walking program alone.",[26,405,406],"Exercise Therapy","High Intensity Interval Training",[75,408,409],"high intensity interval training","moderate intensity continuous training","2025-12-20",{"date":412,"type":32},"2026-01-06",{"date":414,"type":21},"2025-12-25",{"date":269,"type":21},{"name":168,"class":39},{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":138},"100487581","vascular-lab-resource-vlr-biorepository-100487581","NCT05628948","Vascular Lab Resource (VLR) Biorepository","Vascular Lab Resource (VLR) Biorepository Study","Inclusion Criteria:\n\n1. 18 years or older\n2. Subjects capable of providing informed consent document\n3. Subjects with diagnosed with or at risk for cardiovascular and metabolic diseases\n\nExclusion Criteria:\n\n1. Known life expectancy of ≤ 6 months at the time of enrollment\n2. Known current pregnancy\n3. Severe Anemia (last documented hemoglobin \\\u003C 7.0 g\u002FdL)",{"count":425,"type":21},500,"This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration.",[428,429,430,431,432,208,433,307,26,434,435,436,437,438,439,440],"Cardiovascular Diseases","Metabolic Disease","Peripheral Artery Disease","Carotid Disease","Aneurysmal Disease","Thrombosis","Non-Atherosclerotic Chronic Arterial Occlusive Disease","Vasculitis","Fibromuscular Dysplasia","Arterial Dissection","May-Thurner Syndrome","Thoracic Outlet Syndrome","Vasospasm","2025-12-15",{"date":443,"type":32},"2025-12-19",{"date":445,"type":32},"2019-11-14",{"date":447,"type":21},"2031-06-30",{"name":449,"class":39},"The Cleveland Clinic",{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":97,"enrollmentInfo":458,"targetDuration":4,"studyType":69,"phases":460,"briefSummary":461,"conditions":462,"keywords":463,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":473,"locationsCount":4},"100611425","eswt-for-primary-lipedema-100611425","NCT07240415","ESWT for Primary Lipedema","Extracorporeal Shockwave Therapy for Primary Lipedema: A Randomized Controlled Trial","ESWT-LIP","Inclusion Criteria:\n\nFemale patients aged 18-65 years Diagnosis of primary lipedema (Stage I-II according to Wold criteria) Stable body weight for the past 3 months Ability to comply with compression garment use Willingness to participate and ability to provide informed consent\n\nExclusion Criteria:\n\nSecondary lipedema or severe venous disease (CEAP C4 or higher) Liposuction or similar procedures within the past 6 months Pregnancy or breastfeeding Active infection, inflammation, or thrombosis Use of high-dose anticoagulants Contraindications to extracorporeal shockwave therapy",{"count":459,"type":21},50,[71],"This randomized controlled clinical trial aims to evaluate the effectiveness of extracorporeal shockwave therapy (ESWT) when added to standard conservative treatment in women with primary lipedema. Participants will be randomly assigned to receive either standard conservative therapy alone or standard therapy combined with radial ESWT. The study will assess changes in pain intensity (VAS), limb circumference measurements, quality of life (SF-36), and patient satisfaction over an 8-week period. Evaluations will be performed at baseline, at the end of the 4-week treatment phase, and at 4-week follow-up. This trial seeks to provide evidence on whether ESWT offers additional clinical benefit in the management of primary lipedema.",[26],[26,464,264,465,466],"Extracorporeal Shockwave Therapy","Radial Shockwave","Chronic Pain","2025-11-16",{"date":469,"type":32},"2025-11-20",{"date":471,"type":21},"2025-12-01",{"date":133,"type":21},{"name":474,"class":39},"Fatih Bagcier",{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":97,"enrollmentInfo":482,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":138},"100575311","investigation-of-central-sensitization-and-associated-factors-in-patients-with-lipedema-100575311","NCT06770634","Investigation of Central Sensitization and Associated Factors in Patients With Lipedema","Investigation of the Prevalence of Central Sensitization and Associated Factors in Patients With Lipedema","Inclusion Criteria:\n\n1. Lipedema; Diagnosis of lipedema Aged between 18 and 65 years Literate Willing to participate in the study\n2. control group; Being completely healthy (no internal\u002Fmetabolic issues such as diabetes, obesity, or hypothyroidism, and no diagnosis of lipedema) BMI ≤ 30 Aged between 18 and 65 years Literate Willing to participate in the study\n\nExclusion Criteria:\n\n1. Lipedema group; Under 18 or over 65 years of age Presence of concurrent lymphedema, chronic venous insufficiency, deep vein thrombosis, polyneuropathy, or fibromyalgia Illiterate Not willing to participate in the study\n2. Control group; Under 18 or over 65 years of age Presence of concurrent lymphedema, chronic venous insufficiency, deep vein thrombosis, polyneuropathy, fibromyalgia, systemic rheumatic diseases, active cancer, infections, or pregnancy Illiterate Not willing to participate in the study",{"count":459,"type":21},"This study aims to investigate the presence of central sensitization and its associated parameters in patients with lipedema. Lipedema is a chronic and hereditary condition that primarily affects the lower extremities in women and is often associated with hormonal changes. Symptoms such as pain, swelling, and tenderness are common in lipedema, and these symptoms may be related to central sensitization. Additionally, the ultrasonographic findings and pain sensitivity in lipedema will be compared with those of healthy individuals. This study seeks to contribute to the diagnosis and treatment process of lipedema.",[26,485],"Central Sensitisation",[487,26],"central sensitization","2025-09-05",{"date":490,"type":32},"2025-09-08",{"date":492,"type":32},"2024-12-06",{"date":494,"type":21},"2025-12-30",{"name":217,"class":39},{"id":497,"slug":498,"hasResults":11,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":504,"enrollmentInfo":505,"targetDuration":4,"studyType":69,"phases":507,"briefSummary":508,"conditions":509,"keywords":510,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":138},"100590239","proof-of-concept-randomized-and-crossover-study-to-assess-the-effectiveness-of-two-types-of-compression-garments-in-lipedema-100590239","NCT06964828","Proof of Concept, Randomized, and Crossover Study, to Assess the Effectiveness of Two Types of Compression Garments in Lipedema","Proof of Concept, Randomized, Controlled, and Crossover Study, to Assess the Effectiveness of Two Types of Compression Garments (Flat vs Circular Knitted) in the Maintenance Treatment of Patients With Lipedema","LipeGar","Inclusion Criteria:\n\n* Clinical diagnosis of lipedema: increased lowe-limb volume, disproportion between upper and lower body, and pain.\n* Lipedema type III stages 1 or 2.\n* Negative pitting sign.\n* In maintenance treatment phase with a class II circular-knitted compression garment for at least 6 months.\n* Adequate compliance with compression garments (worn during the day, except during personal hygiene and water-related activities).\n* Written informed consent to participate.\n\nExclusion Criteria:\n\n* Lipedema with fatty lobulations.\n* Body Mass Index (BMI) ≥ 30 kg\u002Fm2.\n* Waist-to-Height Ratio \\> 0.53.\n* Pregnancy.\n* Renal, hepatic, or cardiac insufficiency.\n* Thrombosis in the lower extremities.\n* Infection in the lower extremities.\n* Active oncological process.\n* Current treatment with corticosteroids and other medications that promote fluid retention.\n* Inability to read the Patient Information Form (HIP) and\u002For provide consent to participate in the study.","70 Years",{"count":506,"type":21},34,[71],"The goal of this prospective randomized crossover experimental study is to assess the effectiveness and tolerance of circular and flat fabric garments in stabilizing lower-limb volume in lipedema. It will assess the effectiveness of the garments and determine any differences between both types of hosiery currently used in routine clinical practice. Participants will be prescribed either circular or flat-knitted pantyhose and wear them daily for 6 months. After 6 months, they will change the type of garment.",[26],[26,511,512],"Compression garments","Maintenance treatment","2025-05-09",{"date":515,"type":32},"2025-05-14",{"date":517,"type":32},"2024-05-08",{"date":519,"type":21},"2026-07",{"name":521,"class":39},"Isabel Forner-Cordero, MD, PhD",{"id":523,"slug":524,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":16,"sex":64,"minAge":18,"maxAge":529,"enrollmentInfo":530,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":532,"conditions":533,"keywords":536,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":138},"100496059","sarcopenia-and-related-factors-in-lipedema-100496059","NCT05739279","Sarcopenia and Related Factors in Lipedema","Evaluation of Sarcopenia and Associated Factors in Patients with Lipedema","Inclusion Criteria:\n\n* between the ages of 18-85\n* with a diagnosis of lipoedema\n* who agreed to participate in the study\n* having a sociocultural level suitable for participation in the study\n* healthy volunteers in a similar age group for the control group\n\nExclusion Criteria:\n\n* with chronic venous insufficiency and\u002For lymphedema\n* with Parkinson's disease, previous stroke, cerebellar diseases, multiple sclerosis, major depression, neuromuscular diseases, history of major orthopedic surgery, severe hip\u002Fknee osteoarthritis, rheumatological diseases, malignancies, advanced heart\u002Fliver\u002Frenal failure, visual impairment, and vestibular diseases, and those who use any assistive device to walk\n* who are illiterate and have cognitive impairment that will prevent them from giving written consent will not be included in the study","85 Years",{"count":531,"type":21},102,"Lipedema is a common disease of subcutaneous adipose tissue. The most common complaint of patients with swelling in the affected extremity is pain. In addition, patients with lipedema may experience conditions that can greatly affect the health and quality of life of the individual, such as loss of muscle strength and exercise capacity, and deterioration in activity levels of daily living. It is still unknown whether the decrease in muscle strength in patients with lipedema is part of this condition or whether decreased activity levels lead to decreased muscle strength.\n\nSarcopenia is an important health problem characterized by age-related loss of muscle mass and muscle function. The relationship between muscle weakness and sarcopenia in patients with lipedema has not been investigated before. Early recognition of possible sarcopenia and functional limitations in these patients may be important to increase the ability of patients to participate in physical activity as part of their conservative management.\n\nThere is no study in the literature investigating sarcopenia in patients with a diagnosis of lipedema. The aim of this study is to evaluate patients with a diagnosis of lipedema in terms of sarcopenia. In addition, the relationship between sarcopenia and age, body mass index, exercise frequency, lipedema type, and stage will be investigated in patients diagnosed with lipedema.",[26,534,535],"Sarcopenia","Musculoskeletal Diseases",[26,534,535],"2025-03-09",{"date":539,"type":32},"2025-03-12",{"date":541,"type":32},"2023-01-01",{"date":543,"type":21},"2025-12",{"name":545,"class":39},"Dokuz Eylul University",{"id":547,"slug":548,"hasResults":11,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":11,"sex":64,"minAge":18,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":69,"phases":555,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":138},"100578489","effects-of-exercise-in-patients-with-lipedema-100578489","NCT06811961","Effects of Exercise in Patients with Lipedema","Effects of Exercise on Edema, Pain, Exercise Capacity, Lower Extremity Muscle Strength and Function in Patients with Lipedema","Inclusion Criteria:\n\n* Having a diagnosis of Lipedema,\n* Patients with Lipedema stage 1,2 and 3\n\nExclusion Criteria:\n\n* Individuals with cardiopulmonary, rheumatic or neurological diagnoses that have symptoms severe enough to prevent participation in exercise,\n* History of cancer, surgery or trauma that may affect the circulatory system,\n* History of liposuction or orthopedic surgery within the last year,\n* Individuals who cannot mobilize independently.",{"count":554,"type":21},20,[71],"Lipedema is a chronic progressive disease characterized by symmetrical, disproportionate swelling of subcutaneous adipose tissue, which is common in women and mostly seen in the lower extremities and to a lesser extent in the upper extremities. Healthy lifestyle approaches including exercise treatments are very important for lipedema patients in order to prevent disease progression. The aim of this study is to investigate the effects of exercise on edema, pain, exercise capacity, lower extremity muscle strength and function in lipedema patients. Sociodemographic information of the patients, body composition with Tanita InnerScan BC-601-CG device, clinical information regarding lipedema, type and stage of lipedema, inspection, palpation findings will be recorded. Local tissue water percentage will be assessed using Moisturemeter-d compact (MMDc, Delfin Technologies, Kuopio, Finland) device, circumference measurement using tape, pain intensity with Visual Analog Scale, pain threshold with Baseline brand digital algometer device. Muscle strength will be assessed using K-Force hand dynamometer. Functional exercise capacity will be assessed with the 6-minute walk test (6MWT), and lower extremity dysfunction with the lower extremity functional scale. After the assessments are made, the patients will be randomly divided into 2 groups. The patients in the study group will perform group exercises consisting of warm-up, loading and cool-down periods of 40-50 minutes, 2 days a week for 6 weeks, and strengthening exercises applied to the hip muscles and knee extensors with elastic resistance bands, which are decided according to the level of effort perceived by the patient, 3 sets of 10 repetitions, 2 days a week for 6 weeks. The same assessments will be applied to the patients again at the end of the exercise program. The control group will be re-evaluated after 6 weeks with suggestions regarding lipedema and physical activity level, and the obtained data will be compared.",[26],[75,126,559],"function","2025-02-02",{"date":562,"type":32},"2025-02-06",{"date":564,"type":32},"2024-10-05",{"date":566,"type":21},"2025-02-05",{"name":568,"class":39},"Ilke Keser"]